May 21, 2026 —
Eli Lilly has acquired Engage Biologics, a preclinical biotechnology company developing non-viral DNA delivery technology for genetic medicines. The transaction is valued at up to $202 million in cash, including an upfront payment and additional development milestone payments.
Engage’s core technology is the Tethosome platform, a non-viral DNA delivery system designed to improve the potency, tolerability, and redosability of DNA-based genetic medicines. The platform combines engineered DNA payloads with lipid nanoparticle delivery and an mRNA-encoded proprietary Tethosome technology intended to enhance nuclear localization and increase gene expression.
Non-viral DNA delivery has long been attractive because DNA-based therapies can offer durability and programmability, while avoiding some limitations associated with viral vectors. However, the field has faced challenges around efficient nuclear delivery, expression potency, innate immune sensing, tolerability, and repeat dosing. Engage’s Tethosome platform is designed to address these limitations by improving intracellular localization and expression while engineering DNA payloads for better tolerability.
The acquisition adds another delivery technology to Lilly’s expanding genetic medicines portfolio. Lilly has been increasingly active in the genetic medicine space, including RNA, gene editing, and non-viral delivery technologies. By integrating Engage’s platform with Lilly’s broader R&D and development capabilities, the company aims to accelerate the creation of new genetic therapies that could benefit from durable expression without relying on viral vector delivery.
The deal also reflects a broader industry trend: delivery remains one of the central bottlenecks in genetic medicine. As the field expands beyond traditional viral vectors and transient RNA therapies, non-viral DNA platforms may become increasingly important for programs that require longer expression, repeat dosing, and scalable manufacturing.
If successfully developed, Tethosome-enabled delivery could help open a new class of non-viral genetic medicines that combine the durability of DNA with the flexibility of LNP-based delivery. While Engage’s programs remain preclinical, Lilly’s acquisition underscores growing confidence that next-generation delivery platforms will play a defining role in the future of genetic medicine.
